Clinical trials with recombinant allergens--three perspectives: industry

Arb Paul Ehrlich Inst Bundesinstitut Impfstoffe Biomed Arzneim Langen Hess. 2009:96:270-5; discussion 275-8.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Clinical Trial, Phase III
  • Randomized Controlled Trial

MeSH terms

  • Allergens / administration & dosage
  • Allergens / therapeutic use*
  • Antigens, Plant / administration & dosage
  • Antigens, Plant / therapeutic use
  • Betula / adverse effects
  • Betula / immunology
  • Desensitization, Immunologic / methods*
  • Drug Industry
  • Humans
  • Plant Proteins / administration & dosage
  • Plant Proteins / immunology
  • Plant Proteins / therapeutic use
  • Pollen / immunology
  • Recombinant Proteins / administration & dosage
  • Recombinant Proteins / immunology*
  • Recombinant Proteins / therapeutic use*
  • Rhinitis, Allergic, Seasonal / immunology
  • Rhinitis, Allergic, Seasonal / therapy

Substances

  • Allergens
  • Antigens, Plant
  • Plant Proteins
  • Recombinant Proteins